Key clinical point: Poziotinib demonstrated promising antitumor activity but high toxicity in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (BC) who were heavily pretreated with HER2-directed therapy.
Major finding: Intermittent and continuous dosing schedules of poziotinib led to objective response rates of 30% each ( P = .98) and disease control rates of 60% and 78% ( P = .15), respectively. Grades 3-4 treatment-related adverse events were reported by 67% and 76% of patients receiving intermittent and continuous dosing schedules of poziotinib, respectively.
Study details: This phase 2 trial included 67 patients with HER2+ advanced BC who were previously treated with two or more HER2-directed regimens and who received 24 mg poziotinib once daily on an intermittent dosing schedule (n = 33) or 16 mg poziotinib once daily on a continuous dosing schedule (n = 34) .
Disclosures: This study received financial support from Spectrum Pharmaceuticals. Gajanan Bhat and Szu-Yun Leu declared being employees of Spectrum Pharmaceuticals. Adam Brufsky declared serving as a consultant for and receiving research support from various sources. The other authors did not declare any conflicts of interest.
Source: Nasrazadani A, Marti JLG, Lathrop K, et al. Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens. Breast Cancer Res Treat. 2024 (Jan 23). doi: 10.1007/s10549-023-07236-z Source